1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
Delayed Swiss Exchange  -  05/25 12:48:59 pm EDT
333.00 CHF   +0.47%
05/25Roche's Polivy Receives EU Approval for Lymphoma Treatment
MT
05/25Roche develops test kits to detect monkeypox virus
RE
05/25Roche Develops PCR Tests to Detect Monkeypox Virus
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche : virtual event on key ophthalmology data presented at the Angiogenesis 2022 Meeting

01/17/2022 | 08:05am EDT
Investor Update Roche's virtual event on key ophthalmology data presented at the Angiogenesis 2022 Meeting


We are pleased to invite investors and analysts to participate in our virtual event on Monday,
14 February 2022,
highlighting Roche data presented at the virtual Angiogenesis, Exudation, and Degeneration 2022 Meeting, from 11th to 12th February.

16:30 - 17:45 CET / 15:30 - 16:45 GMT
10:30 - 11:45 am EST / 7:30 - 8:45 am PST

The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 15:00 CET on the day of the event.
> click here

Access to virtual event (pre-registration required)
Please pre-register for our webinar here*.

Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.

A replay of the webcast will be available via > ir.roche.com

*privacy notice

Best regards,

Bruno Eschli
Head of Investor Relations

Sabine Borngräber
Investor Relations Officer

Roche Investor Relations
Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: karl.mahler@roche.com

Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com

Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com

Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com

Disclaimer

Roche Holding AG published this content on 17 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 January 2022 13:04:16 UTC.


© Publicnow 2022
All news about ROCHE HOLDING AG
05/25Roche's Polivy Receives EU Approval for Lymphoma Treatment
MT
05/25Roche develops test kits to detect monkeypox virus
RE
05/25Roche Develops PCR Tests to Detect Monkeypox Virus
DJ
05/25CORRECTION : Roche Develops PCR Tests for Monkeypox Virus Research
MT
05/25Roche Develops PCR Tests for Monkeypox Virus Research
MT
05/25Roche develops test kits to detect monkeypox virus
RE
05/25Roche's Polivy combination approved by European Commission for people with previously u..
AQ
05/25Roche develops unique PCR tests to detect the monkeypox virus
AQ
05/25Alembic Pharmaceuticals receives USFDA Final Approval for Pirfenidone Tablets, 267 mg a..
AQ
05/24GLOBAL MARKETS LIVE : Broadcom, Airbnb, Roche, Toyota, Uber
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2022 63 642 M 66 127 M 66 127 M
Net income 2022 14 819 M 15 398 M 15 398 M
Net Debt 2022 10 926 M 11 353 M 11 353 M
P/E ratio 2022 17,8x
Yield 2022 2,91%
Capitalization 271 B 282 B 282 B
EV / Sales 2022 4,43x
EV / Sales 2023 4,26x
Nbr of Employees 100 920
Free-Float 82,4%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 333,00 CHF
Average target price 393,49 CHF
Spread / Average Target 18,2%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Levi A. Garraway Chief Medical Officer
Pascale Schmidt Chief Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG-12.57%281 908
JOHNSON & JOHNSON5.00%477 336
PFIZER, INC.-9.04%299 678
ELI LILLY AND COMPANY11.15%275 413
ABBVIE INC.12.23%263 494
NOVO NORDISK A/S1.61%244 637